Compare BridgeBio Pharma Inc (BBIO) vs RLX Technology Inc (RLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs RLX Technology Inc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while RLX Technology Inc trades at $1.98 (market cap $2.44B). The key difference: BridgeBio Pharma Inc is far larger — about 6.8× RLX Technology Inc's market cap, and RLX Technology Inc pays a 5% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | RLX | |
|---|---|---|
Market Cap | $16.61B | $2.44B |
Sector | Health | Technology |
52-Week High | $90.17 | $2.73 |
52-Week Low | $47.29 | $1.79 |
Enterprise Value | $18.16B | $1.07B |
Dividend Yield | — | 5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
RLX Technology trades at $2.01, up 1.01% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q1 2026 revenue growth to $4.4B with a net profit margin of 22.47%, though it missed EPS estimates for three consecutive quarters. Recent news highlights international expansion, including European integration and a 70% international revenue share.
Outlook is mixed: strong fundamentals with cash flow from operations and no debt support growth, but earnings misses and regulatory risks in the vaping industry pose challenges. The sole analyst coverage recommends Hold, reflecting cautious optimism amid execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About RLX Technology Inc
RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →
